BrainsWay Ltd. (BWAY)
NASDAQ: BWAY · Real-Time Price · USD
11.89
-0.34 (-2.78%)
At close: Oct 6, 2026, 4:00 PM EDT
11.85
-0.04 (-0.34%)
Pre-market: Oct 7, 2026, 5:34 AM EDT
BrainsWay Revenue
BrainsWay had revenue of $17.11M in the quarter ending June 30, 2026, with 35.43% growth. This brings the company's revenue in the last twelve months to $60.70M, up 31.71% year-over-year. In the year 2025, BrainsWay had annual revenue of $52.23M with 27.33% growth.
Revenue (ttm)
$60.70M
Revenue Growth
+31.71%
P/S Ratio
7.92
Revenue / Employee
$470,504
Employees
129
Market Cap
480.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 52.23M | 11.21M | 27.33% |
| Dec 31, 2024 | 41.02M | 9.23M | 29.04% |
| Dec 31, 2023 | 31.79M | 4.61M | 16.96% |
| Dec 31, 2022 | 27.18M | -2.48M | -8.36% |
| Dec 31, 2021 | 29.66M | 7.60M | 34.46% |
| Dec 31, 2020 | 22.06M | -1.04M | -4.52% |
| Dec 31, 2019 | 23.10M | 6.70M | 40.89% |
| Dec 31, 2018 | 16.40M | 5.25M | 47.12% |
| Dec 31, 2017 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tactile Systems Technology | 350.31M |
| OrthoPediatrics | 252.72M |
| Cerus | 221.55M |
| NeuroPace | 106.99M |
| Delcath Systems | 95.42M |
| Sight Sciences | 83.38M |
| AVITA Medical | 75.63M |
| 908 Devices | 60.84M |
BWAY News
- 4 weeks ago - BrainsWay Reports Positive Pilot Study Results For Deep TMS In Depression & Early Alzheimer's - Nasdaq
- 4 weeks ago - Brainsway publishes results from pilot study - TheFly
- 4 weeks ago - BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™ - GlobeNewsWire
- 5 weeks ago - Brainsway price target raised to $19 from $17 at H.C. Wainwright - TheFly
- 5 weeks ago - Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High? - Nasdaq
- 7 weeks ago - Brainsway (BWAY) Upgraded to Buy: Here's Why - Nasdaq
- 7 weeks ago - Brainsway reports Q2 EPS 7c, consensus 7c - TheFly
- 7 weeks ago - Brainsway raises FY26 revenue view to $68M-$70M from $66M-$68M - TheFly